Trump Orders Federal Push to Fast-Track Psychedelic Drug Research

President Donald Trump signed an executive order on Saturday that directs multiple federal agencies to dramatically accelerate research and access to psychedelic treatments for conditions including post-traumatic stress disorder, depression, and addiction.[1][2] The order aims to remove what Trump administration officials describe as legal impediments that have slowed American researchers from studying these substances.[4] The executive order contains several concrete measures to fund and streamline psychedelic research. The Department of Health and Human Services will allocate $50 million through the Advanced Research Projects Agency for Health (ARPA-H) to match investments made by state governments in psychedelic research programs, particularly targeting populations with serious mental illness.[3] The order also instructs the FDA to prioritize review of psychedelic compounds designated as breakthrough therapies and directs the Drug Enforcement Administration to reduce bureaucratic restrictions on conducting studies with these substances.[2] A significant provision of the order establishes new access pathways for patients with serious illnesses to obtain investigational psychedelic drugs, including ibogaine compounds, before formal FDA approval. The order requires the FDA and DEA to create this pathway for eligible patients whose drugs have met basic safety requirements under the Right to Try Act, which Trump signed into law during his first term.[3] The order also directs the Attorney General to initiate reviews of psychedelic products upon successful completion of Phase 3 clinical trials so they can be rescheduled as soon as possible following FDA approval where appropriate.[3] The executive order emphasizes collaboration between federal agencies and the private sector to expand clinical trial participation and evidence generation. The order requires HHS and the FDA to work with the Department of Veterans Affairs and private sector partners to increase data sharing and clinical trial participation for experimental psychedelic therapies, with particular attention to military veterans.[1][3] This focus on veterans reflects growing interest in psychedelics like MDMA and ibogaine as potential treatments for service-related PTSD and other trauma-related conditions.[4][5] The order builds on recent state-level momentum in psychedelic research legislation. The $50 million federal matching provision may have been partly motivated by Texas's recent enactment of a law requiring publicly-funded ibogaine research.[2] The order also solidifies the potential for FDA Priority Review Vouchers for psychedelic drugs, sending a significant regulatory signal about the administration's commitment to accelerating the drug approval process for these compounds.[2]